Nihon rinsho. Japanese journal of clinical medicine
-
One of the advances in recent years about the treatment of hepatocellular carcinoma is clinical evidence of the molecular target drug, sorafenib. Although sorafenib shows little anti-tumor effect indicated by tumor shrinkage, it has inhibitory effect of tumor development to be the first drug shown to extend survival in hepatocellular carcinoma. ⋯ Position of sorafenib in the treatment of hepatocellular carcinoma among hepatic arterial infusion chemotherapy and transcatheter arterial embolization is not yet clear. Many clinical trials of molecular target drugs against hepatocellular carcinoma are underway.
-
In Japan, about 20 million people were infected with pandemic (H1N1) 2009 virus between July 2009 and March 2010. About 60% of them were under 15 years, but only 38 pediatric deaths were reported. ⋯ The time from onset to appear dyspnea in patients with lower respiratory complications was very short, and encephalopathy also appears very rapidly. It is very important to observe clinical course closely and to start neuraminidase inhibitor within 48 hours.
-
A new pandemic influenza A (H1N1) virus had emerged and rapidly spread throughout the world. The clinical pathological observations associated with severe cases of pandemic (H1N1) 2009 are similar to that of high pathogenic avian influenza (H5N1). In order to find the most effective treatment methods for this pandemic influenza (H1N1), we describe our experiences, investigations and collaboration studies of avian influenza (H5N1) in Vietnam in association of our cooperative study of pandemic (H1N1) 2009 in Mexico. Effective treatment methods for critical illness due to influenza will be discussed from medical, regional and global points of view, which may be applied for the treatment of any type of influenza virus.